ENDO 2025 spotlights breakthrough research in PCOS, obesity, diabetes, and rare endocrine disorders and offers practical updates for daily clinical care. As the sun rises over San Francisco, ...

The FDA has accepted the New Drug Application for ET-600, an oral solution formulation of desmopressin, for the treatment of central diabetes insipidus.

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Compared with those with overweight and normal weight, people with obesity were more likely to report financial hardship and food insecurity.

There is increased risk for incident myocardial infarction among adults aged 18 to 64 years with joint exposure to ozone and increased ambient temperature.

Diabetes remission was more likely and laparoscopic surgery was less likely among women than men with paragangliomas and pheochromocytomas.

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Higher UPF-consumption was linked to worse knee OA outcomes among women, including higher pain scores, worse physical function, and thinner knee cartilage.

There has been an increase in certain cardiometabolic risk factors and a decrease in others among adults in the United States in recent years.

Traditional cardiovascular risk assessment tools underperform among individuals with metabolic dysfunction-associated steatotic liver disease.

Fluctuations in ovarian sex hormones across the menstrual cycle may influence women’s likelihood of alcohol consumption.

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.